Evidence map›Paper›PMID 36936966›Full record

ArticleFrontiers in immunology2023

Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies.

Belén Aparicio, Marta Ruiz, Noelia Casares, Leyre Silva, Josune Egea, Patricia Pérez, Guillermo Albericio, Mariano Esteban, Juan García-Arriaza, Juan J Lasarte and 1 more

Open access · goldFull text readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Belén AparicioCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Marta RuizCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Noelia CasaresCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Leyre SilvaCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Josune EgeaCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Patricia PérezCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Guillermo AlbericioCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Mariano EstebanCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Juan García-ArriazaCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Juan J LasarteCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Pablo SarobeCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Navarre Institute of Health Research · ESConsejo Superior de Investigaciones Científicas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.1044025.].

Indexed as

conserved regionscross-recognizing antibodiesOmicron variantpeptide vaccineSARS-CoV-2

Identifiers

PMID36936966
PMCPMC10020720
OpenAlexW4323044539

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.